1492 Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

1492 Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-19,530	Closed	-$398K	–	114
2016 Q2	$398K	Hold	19,530	–	–	0.36%	64
2016 Q1	$298K	Sell	19,530 -250	-1%	-$3.26K	0.25%	76
2015 Q4	$266K	Hold	19,780	–	–	0.19%	89
2015 Q3	$278K	Sell	19,780 -60,142	-75%	-$1.12M	0.2%	94
2015 Q2	$1.36M	Sell	79,922 -100	-0.1%	-$1.42K	0.86%	29
2015 Q1	$967K	Sell	80,022 -113	-0.1%	-$1.07K	0.56%	47
2014 Q4	$665K	Buy	80,135 +48,700	+155%	+$409K	0.42%	70
2014 Q3	$273K	Buy	31,435 +4,000	+15%	+$36.1K	0.15%	90
2014 Q2	$300K	Hold	27,435	–	–	0.15%	95
2014 Q1	$245K	Buy	+27,435	New	+$253K	0.12%	116

Other funds holding SUPN

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

1492 Capital Management's SUPN Position: Q3 2016 in Review

1492 Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2016, closing a stake of 19,530 shares — an estimated $398K sold.

1492 Capital Management first reported a position in SUPN in Q1 2014 and held it in 10 quarters. The position peaked at $1.36M in Q2 2015. 221 funds tracked by Wall St. Rank hold SUPN as of Q3 2016.

1492 Capital Management reported no remaining Supernus Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
1492 Capital Management sold 19,530 Supernus Pharmaceuticals shares in Q3 2016, an estimated $398K.
1492 Capital Management first reported a position in Supernus Pharmaceuticals in Q1 2014 and held it in 10 quarters.
1492 Capital Management's Supernus Pharmaceuticals position peaked at $1.36M in Q2 2015.
221 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2016.

Based on 1492 Capital Management's 13F filing for Q3 2016, filed 10 Nov 2016.